A detailed history of Norden Group LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Norden Group LLC holds 1,665 shares of VRTX stock, worth $823,525. This represents 0.09% of its overall portfolio holdings.

Number of Shares
1,665
Previous 1,379 20.74%
Holding current value
$823,525
Previous $646 Million 19.8%
% of portfolio
0.09%
Previous 0.13%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 17, 2024

BUY
$460.0 - $505.78 $131,560 - $144,653
286 Added 20.74%
1,665 $774 Million
Q2 2024

Aug 06, 2024

BUY
$392.81 - $485.53 $152,017 - $187,900
387 Added 39.01%
1,379 $646 Million
Q1 2024

Apr 30, 2024

SELL
$407.69 - $446.08 $5.29 Million - $5.78 Million
-12,966 Reduced 92.89%
992 $415 Million
Q1 2024

Apr 19, 2024

BUY
$407.69 - $446.08 $5.44 Million - $5.95 Million
13,343 Added 2169.59%
13,958 $5.83 Billion
Q4 2023

Feb 05, 2024

BUY
$343.0 - $410.68 $210,945 - $252,568
615 New
615 $250 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $127B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Norden Group LLC Portfolio

Follow Norden Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Norden Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Norden Group LLC with notifications on news.